Wearables: A device for poor posture, baby monitors under academic scrutiny;

@FierceMedDev: ICYMI yesterday: Brain tumor treatment device gets early trial halt for efficacy as a combo with chemo. Story | Follow @FierceMedDev

@EmilyWFierce: Shaq is back for $SNY's latest marketing campaign. Release | Follow @EmilyWFierce

> Corpak MedSystems, a medical device company focused on enteral access technologies, acquired France-based Maxter Catheters, developer of disposable medical devices, for an undisclosed amount. Release

> An academic points out that there is no FDA approval or published data supporting claims that wearable baby monitors prevent sudden infant death syndrome (SIDS). Release

> South Korean company creates Arki, a wristband that uses arm swing patterns to detect bad posture and alerts wearer to adjust their posture. Watch

> CoorsTek Medical acquired Italian device manufacturer Nanosurfaces Industries for an undisclosed amount. Release

Biotech News

@FierceBiotech: Agios offers another glimpse of 'exciting' early data for a leukemia drug. Report | Follow @FierceBiotech

@JohnCFierce: Lots of discussion about this one -- Average cost of drug R&D? Try $2.9B on for size. Editor's Corner | Follow @JohnCFierce

@DamianFierce: Knight Therapeutics found a buyer for its FDA priority review voucher, selling it to $GILD for $125M. Release | Follow @DamianFierce

> Sanofi's shortlist of CEO candidates so far has a distinct French accent. Item

> Shire orders 500 staffers to move to Boston-area biotech 'Mecca.' Report

> Bind heralds hope for its nanotech cancer drug after mixed Phase II. Story

> Go-go execs at Gilead nab an FDA priority review voucher for $125M. News

Pharma News

@FiercePharma: Ranbaxy fights FDA for killing its approval to make generic Nexium. FiercePharmaManufacturing story | Follow @FiercePharma

@CarlyHFierce: AirFluSal Forspiro won approval in my two favorite countries, Ireland & Czech Republic, which is inconsequential to me but fun nonetheless. | Follow @CarlyHFierce

> Novartis seeks tech partners for brave new beyond-the-pill world. More

> Solo Shire moves 500 to Boston as it pushes ahead with reorg. Story

> NICE asks Novartis to pony up more information on Xolair for hives. Report

Drug Delivery News

> Cynapsus releases clinical trial data about its sublingual thin-film strip for Parkinson's. Item

> Catalent buys particle engineering outfit Micron Technologies. News

> RNAi masking technique allows more efficient delivery. Story

> Medical marijuana company licenses RapidMist device for buccal delivery. Report

> NSF funds further research into only FDA-cleared catheter for rectal delivery. Article

Diagnostics News

> Precision Therapeutics ropes in $60M for corporate overhaul. More

> Cepheid snags $3.3M to roll out rapid Ebola test. Report

> Roche nabs FDA clearance for quick strep test. News

> Illumina, Sequenta partner up on next-gen cancer diagnostic. Article

> Enterome teams up with AbbVie to create molecular Dx for Crohn's disease. Item

Pharma Marketing News

> Payers' hep C delay tactics work: Coverage hurdles may be dampening Harvoni script growth. Article

> How to prep for a 'megablockbuster' launch? Novartis lines up cost-savings data. Report

> Valeant and Allergan's wining-and-dining shows docs still hold the script reins. More

> Painkiller marketing secrets? Check Chicago's unredacted suit against Endo, Purdue, Cephalon, et al. Story

> Sanofi tags newly OK'd MS drug Lemtrada at $158K, ready to tout head-to-head Rebif data. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.